Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 25:25:e38680.
doi: 10.2196/38680.

Effectiveness of the Lilly Connected Care Program in Improving Glycemic Management Among Patients With Type 2 Diabetes in China: Retrospective Real-world Study

Benli Su #  1 , Yu Chen #  2 , Xingping Shen #  3 , Jianchao Guo  2 , Yuchen Ding  4 , Xiao Ma  4 , Yuxin Yang  4 , Dongfang Liu  5
Affiliations

Effectiveness of the Lilly Connected Care Program in Improving Glycemic Management Among Patients With Type 2 Diabetes in China: Retrospective Real-world Study

Benli Su et al. J Med Internet Res. .

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a worldwide public health concern. Mobile health management platforms could be a potential way to achieve effective glycemic control.

Objective: This study aimed to evaluate the real-world effectiveness of the Lilly Connected Care Program (LCCP) platform in glycemic control among patients with T2DM in China.

Methods: This retrospective study included Chinese patients with T2DM (aged ≥18 years) from April 1, 2017, to January 31, 2020, for the LCCP group and from January 1, 2015, to January 31, 2020, for the non-LCCP group. Propensity score matching was used to match the LCCP and non-LCCP groups to reduce confounding, with covariates including age, sex, the duration of diabetes, baseline hemoglobin A1c (HbA1c), and the number of oral antidiabetic medication classes. HbA1c reduction over 4 months, the proportions of patients achieving an HbA1c reduction of ≥0.5% or ≥1%, and the proportions of patients reaching to target HbA1c level of ≤6.5% or <7% were compared between the LCCP and non-LCCP groups. Multivariate linear regression was used to assess factors associated with HbA1c reduction.

Results: A total of 923 patients were included, among whom 303 pairs of patients were well matched after propensity score matching. HbA1c reduction during the 4-month follow-up was significantly larger in the LCCP group than the non-LCCP group (mean 2.21%, SD 2.37% vs mean 1.65%, SD 2.29%; P=.003). The LCCP group had a higher proportion of patients with an HbA1c reduction of ≥1% (209/303, 69% vs 174/303, 57.4%; P=.003) and ≥0.5% (229/303, 75.6% vs 206/303, 68%; P=.04). The proportions of patients reaching the target HbA1c level of ≤6.5% were significantly different between the LCCP and non-LCCP groups (88/303, 29% vs 61/303, 20.1%; P=.01), whereas the difference in the proportions of patients reaching the target HbA1c level of <7% was not statistically significant (LCCP vs non-LCCP: 128/303, 42.2% vs 109/303, 36%; P=.11). LCCP participation and higher baseline HbA1c were associated with a larger HbA1c reduction, whereas older age, longer diabetes duration, and higher baseline dose of premixed insulin analogue were associated with a smaller HbA1c reduction.

Conclusions: The LCCP mobile platform was effective in glycemic control among patients with T2DM in China in the real world.

Keywords: LCCP; Lilly Connected Care Program; T2DM; diabetes management; hemoglobin A1c; real-word study; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: YD, XM, and YY are employees and shareholders of Eli Lilly and Company. The other authors have no conflicts of interest to declare.

References

    1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271–281. doi: 10.1016/j.diabres.2018.02.023.S0168-8227(18)30203-1 - DOI - PubMed
    1. Teo ZL, Tham Y, Yu M, Chee ML, Rim TH, Cheung N, Bikbov MM, Wang YX, Tang Y, Lu Y, Wong IY, Ting DSW, Tan GSW, Jonas JB, Sabanayagam C, Wong TY, Cheng C. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021 Nov;128(11):1580–1591. doi: 10.1016/j.ophtha.2021.04.027.S0161-6420(21)00321-3 - DOI - PubMed
    1. Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Bärnighausen Till, Vollmer S. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017 Jun;5(6):423–430. doi: 10.1016/S2213-8587(17)30097-9.S2213-8587(17)30097-9 - DOI - PubMed
    1. Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen Till, Davies J, Vollmer S. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018 May;41(5):963–970. doi: 10.2337/dc17-1962.dc17-1962 - DOI - PubMed
    1. Pan X R, Yang W Y, Li G W, Liu J, National Diabetes Prevention and Control Cooperative Group Prevalence of diabetes and its risk factors in China, 1994. Diabetes Care. 1997 Nov;20(11):1664–9. doi: 10.2337/diacare.20.11.1664. - DOI - PubMed

Publication types